Wikidata

(Q63817414)

English

Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma

clinical trial

In more languages

Statements

title
An Open-label, Randomized, Multi-center, Phase III Study to Compare the Safety and Efficacy of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma After Failure of Anti-angiogenic (VEGF-targeted and mTOR Inhibitor) Therapies (English)
0 references
sponsor
Novartis
0 references
country
Argentina
0 references
Australia
0 references
Austria
0 references
Belgium
0 references
Brazil
0 references
Canada
0 references
Colombia
0 references
Czech Republic
0 references
France
0 references
Germany
0 references
Greece
0 references
Hungary
0 references
Israel
0 references
Italy
0 references
Japan
0 references
Netherlands
0 references
Norway
0 references
Poland
0 references
Saudi Arabia
0 references
Slovakia
0 references
Spain
0 references
Sweden
0 references
Switzerland
0 references
Thailand
0 references
United Kingdom
0 references
start time
March 2011
0 references
end time
June 2014
0 references
number of participants
564
0 references
minimum age
18 year
0 references

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit
                    Retrieved from "https://www.wikidata.org/w/index.php?title=Q63817414&oldid=1942037589"